Laurus Labs shares touched a record high of ₹2,087 on Monday, marking a 128% gain from February lows. Market optimism is centered on the company's upcoming second-quarter results on October 29, 2026. Investors are betting on strong growth in the CDMO division and improved profit margins as the company expands into advanced therapies like peptides and antibody-drug conjugates.
Laurus Labs shares reached a new peak of ₹2,087 during Monday's trading session, standing out while the broader market faced pressure. The stock has seen significant momentum, rallying 128% from its lows in February 2026. This price movement comes just before the company’s scheduled board meeting on October 29, 2026, where it will announce its financial performance for the quarter ending September 30, 2026, and discuss potential interim dividend payouts.
Analytical Outlook for Second Quarter
Financial analysts have high expectations for the company's second-quarter performance. Data from Kotak Institutional Equities projects that revenue in the Synthesis segment could rise by 86% year-on-year to reach ₹880 crore. Additionally, the company is expected to see an 11% increase in its Active Pharmaceutical Ingredient (API) sales, driven by demand for non-ARV products. A key area for investors to monitor will be the reported improvement in margins, with projections suggesting a 680 basis point increase in EBITDA margins to 31.2%.
Strategic Expansion in CDMO
The company has undergone a structural shift, significantly scaling its Contract Development and Manufacturing Organization (CDMO) business. Over the past two years, the quarterly revenue run rate for this division has grown from the ₹220–250 crore range to approximately ₹800 crore. Management is focusing on high-value areas such as peptides, gene therapies, and antibody-drug conjugates. This expansion is designed to capture business from global pharmaceutical innovators looking to diversify their supply chains.
Sector Trends and Monitorables
Broader trends in the Indian pharmaceutical sector remain positive as global firms look to reduce reliance on single-country suppliers. While the industry has occasionally faced pressure from inventory destocking, demand for specialized manufacturing services remains steady. Estimates indicate the Indian CDMO segment, currently valued at roughly $3.5 billion, has the potential for long-term growth toward $25 billion by 2035.
Investors may want to watch for the sustainability of these margins, as API and raw material prices can often cause volatility in the pharmaceutical sector. Additionally, while the shift toward advanced modalities like antibody-drug conjugates is a key growth driver, it also requires careful project execution to meet global standards. The upcoming earnings release will provide clarity on whether the company’s operational improvements have translated into sustained cash flow and profit growth.